Table of contents
- Clinical trial overview
- Who the trial is for
- Phase and study endpoints
- Study design and treatment plan
- What the researchers are measuring
- What this means for patients
Clinical trial overview
The available study is an interventional trial of Hdp-101 in patients with plasma cell disorders, including multiple myeloma.[1] The trial is titled as a first-in-human study, which means it is the first time this treatment is being tested in people in this research program.[1]
The trial is authorised and has a planned enrollment of 173 participants.[1]
Who the trial is for
The study focuses on patients with relapsed or refractory multiple myeloma (r/r MM).[1] Relapsed means the disease has come back after treatment, and refractory means it has not responded well to treatment.[1]
The trial title also says it includes patients with plasma cell disorders, so the research is not limited to one exact group only, but multiple myeloma is the main condition named in the study details.[1]
Phase and study endpoints
This is a Phase 1/2 study.[1] Phase 1 is mainly used to learn about safety and to find the dose that patients can tolerate, while Phase 2a looks for early signs that the treatment may help.[1]
The Phase 1 main endpoint is the number of patients who have a dose-limiting toxicity during the first treatment cycle.[1] A dose-limiting toxicity is a side effect serious enough to stop the dose from being increased.[1]
The Phase 2a main endpoint is objective response rate (ORR).[1] ORR shows how many patients have a measurable improvement in their cancer, such as shrinkage or disappearance of disease.[1]
Study design and treatment plan
The trial is described as a first-in-human study to evaluate safety, tolerability, pharmacokinetics, and efficacy of Hdp-101.[1] Tolerability means how well patients can handle the treatment, and pharmacokinetics means how the body handles the treatment over time.[1]
The brief summary says Phase 1 is meant to determine the maximum tolerable dose for each treatment arm and/or select a recommended Phase 2 dose for Hdp-101 as monotherapy in patients with relapsed or refractory multiple myeloma.[1] Monotherapy means the treatment is given alone, not with another drug in the same study plan.[1]
The intervention listed is Hdp-101 for intravenous use, which means it is given through a vein.[1]
What the researchers are measuring
The study is designed to answer two main questions: first, is Hdp-101 safe enough to continue testing, and second, does it show signs of helping patients with multiple myeloma?[1]
Safety: the trial checks for harmful effects, especially dose-limiting toxicity in Phase 1.[1]
Dose finding: the study aims to identify the maximum tolerable dose and a recommended Phase 2 dose.[1]
Early efficacy: the trial measures objective response rate in Phase 2a to see whether the cancer responds to treatment.[1]
Pharmacokinetics: the study also looks at how the body processes Hdp-101 over time.[1]
What this means for patients
For patients, this trial is an early research study that is trying to learn whether Hdp-101 can be used safely and whether it may help people whose multiple myeloma has returned or stopped responding to treatment.[1] Because it is a Phase 1/2 study, the first goal is not to prove full benefit, but to gather early safety and activity data.[1]
The study is already authorised and plans to include 173 people, so it is a fairly large early-stage trial.[1]
